

30. The compound of claim 1 or 2, wherein the compound is



or a pharmaceutically acceptable salt thereof.

31. The compound of claim 1 or 2, wherein the compound is



or a pharmaceutically acceptable salt thereof.

32. A composition comprising a compound of any of the preceding claims.

33. The use of a compound or composition according to any one of claims 1-32 in the manufacture of a medicament.

34. The use of a compound or composition according to any one of claims 1-32 in the manufacture of a medicament for the treatment of a disease or condition mediated by cancer Osaka thyroid (Cot) in a human patient.

35. The use according to claim 34 wherein said disease or condition is selected from cancer, diabetes, inflammatory disease and inflammatory bowel disease (IBD).

36. The use according to 34, wherein the disease or condition is a liver disease.

37. The use according to claim 35 wherein said disease or condition is a solid tumor selected from pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, and soft tissue sarcoma.

38. The use according to claim 35 wherein said disease or condition is selected from type 1 and type 2 diabetes, gestational diabetes, prediabetes, insulin resistance, metabolic syndrome, impaired fasting glycaemia and impaired glucose tolerance.

39. The use according to claim 35 wherein said disease or condition is selected from systemic lupus erythematosus (SLE), myestenia gravis, rheumatoid arthritis (RA), acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis (MS), inflammatory bowel disease (IBD), sepsis, psoriasis, Sjoegren's syndrome, autoimmune hemolytic anemia, asthma, or chronic obstructive pulmonary disease (COPD), ankylosing spondylitis, reactive arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, juvenile arthritis, juvenile onset rheumatoid arthritis, juvenile rheumatoid and psoriatic arthritis.

40. The use according to claim 35 wherein said disease or condition is selected from diversion colitis, ischemic colitis, infectious colitis, chemical colitis, microscopic colitis (including collagenous colitis and lymphocytic colitis), atypical colitis, pseudomembranous colitis, fulminant colitis, autistic enterocolitis, indeterminate colitis, Behçet's disease, gastroduodenal CD, jejunoileitis, ileitis, ileocolitis, Crohn's (granulomatous) colitis, irritable bowel syndrome, mucositis, radiation induced enteritis, short bowel syndrome, celiac disease, stomach ulcers, diverticulitis, pouchitis, proctitis, and chronic diarrhea.

41. The use according to claim 35 wherein said disease or condition is systemic lupus erythematosus (SLE), lupus nephritis, lupus-related, and autoimmune disorders or a symptom of SLE.

42. The use according to claim 34 wherein said disease or condition is a chronic intrahepatic or extrahepatic cholestatic condition, liver fibrosis, a chronic or obstructive inflammatory disorder of the liver,liver cirrhosis, liver steatosis or an associated syndrome, a cholestatic or fibrotic effect that is associated with alcohol-induced cirrhosis or with a viral-

borne form of hepatitis, acute or chronic liver failure, liver ischemia after major liver resection, chemotherapy associated steatohepatitis (CASH), Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC), a neoplastic diease of the gastrointestinal tract or liver, diabetic kidney disease (DKD), Non-Alcoholic Fatty Liver Disease (NAFLD), or Non-Alcoholic Steatohepatitis (NASH).